view fairli unev quarter cl result
larg in-lin expect fundament improv
begin bear fruit organ sale growth improv
fastest growth quarter gross margin inflect
posit y/i quarter ahead expect top-lin beat
driven acceler emerg market vs
though cl growth still lag peer note
unilev report growth em share loss
continu global addit flow-
improv fundament management maintain
ep guidanc -msd despit better outlook organ sale
growth upper end prior rang slightli
lower tax rate highlight cost cl drive
growth look forward believ investor begin shift
focu forecast organ sale growth slow
cl lap signific product re-launch face
tougher comp believ cl improv date broadli
reflect current valuat share trade
price-to-earnings premium xlp/ vs year
histor averag howev reflect improv
organ sale growth outlook rais price target
maintain market perform rate larg valuat
ep in-lin cl report adj ep y/i
in-lin our/con est overal ebit
forecast sg tax benefit put ep in-
line estimate takeaway includ organ sale growth
acceler improv vs easier comp
hold stack flat sequenti price improv
vs price posit everi segment
share loss continu key countri includ brazil
mexico china gross margin y/i time
quarter y/i better expect cost save
guidanc maintain cl expect organ sale growth toward
high-end prior rang net sale flat lsd gross
margin tax rate prior ep
msd maintain ep est
focus growth mgmt goal
improv organ sale growth focus innov
increas pace innov make bigger bet
premium evolv portfolio toward premium higher
margin product price includ revenu growth
manag review price/pack architectur similar ko
optimist competit environ chang
concern stepped-up invest
continu requir support futur top-lin growth similar
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud restructur charg one-tim item
compani data secur llc estim reuter
ep in-lin expect cl report adjust ep y/i in-lin
our/consensu estim overal ebit forecast sg tax
benefit put ep in-lin estim
organ sale growth ahead expect organ sale growth ahead
our/consensu estim growth improv sequenti vs
easier y/i comp leav stack unchang growth remain fairli balanc
volum pricing/promo sequenti improv organ sale growth
driven emerg market acceler vs develop market
growth slow sequenti cl post posit organ sale growth
categori e-comm growth strong quarter cl manag note
compani e-commerc busi continu deliv growth well excess categori
drive signific toothpast market share gain ytd
addit segment-by-seg data point segment organ sale growth in-lin
beat estim segment latin america vs estimate north america
vs estimate europ vs estimate asia pacif vs estimate africa
eurasia vs estimate hill vs estimate addit segment detail
follow
latin america organ sale growth in-lin estim
volum price fx headwind cl saw organ
sale growth everi hub second consecut quarter incl mexico brazil
manag note underli categori growth rate latin america remain modestli
posit improv vs cl manag also stress compani remain
commit premium compani portfolio colgat total relaunch
manag attribut strong price growth quarter colgat total
relaunch addit oral person premium innov across portfolio
compani on-going revenu growth manag initi overal oper profit
decreas higher gross profit primarili reflect cost save cl
funding-the-growth initi higher price partial off-set higher raw packag
materi cost incl fx transact cost higher sg reflect higher overhead expens
increas advertis invest cl gain toothpast market share colombia dominican
republ hondura paraguay panama
north america organ sale growth slightli estim
volum price increas fx headwind oral
growth primarili led cl toothpast busi colgat total relaunch help
drive signific posit price cl person growth led compani pca skin
eltamd profession skin care busi continu deliv strong growth
fabuloso continu strong perform reach highest ever market share
 manag also confid cl inventori level note
inventori issu cl nice growth non-track channel
particularli within toothpast oper profit margin declin basi point
lower gross profit primarili reflect higher raw packag materi cost partial off-set
cost save cl funding-the-growth initi higher sg expens primarili
due higher overhead expens primarili relat higher logist cost increas
europ organ sale growth remain mute in-lin estim
volum flat vs last year price fx headwind volum
gain spain greec off-set volum declin germani franc cl
manag note see sequenti market share improv follow
colgat total relaunch key market uk spain itali person
compani sanex physiolog line bring pharmaci trend mass channel drive
increment share bodi cleans oper profit even last year higher
segment gross profit primarili reflect cost save cl funding-the-growth
initi partial off-set higher raw packag materi cost higher sg
expens reflect higher overhead expens increas advertis invest cl gain
toothpast market share unit kingdom itali spain greec netherland
asia pacif organ sale growth slightli ahead estim
volum price fx headwind china remain
drag segment result offset growth across compani hub said
manag note result china improv sequenti despit neg cl
continu focu optim compani distribut network manag call
strong perform across compani natur toothpast brand india thailand
elsewher compani south pacif busi benefit strong price colgat
total relaunch oper profit declin higher sg expens primarili
reflect due higher overhead expens driven combin fx transact
gain increas advertis invest cl gain toothpast market share
philippin australia pakistan
africa eurasia organ sale growth well ahead estim
volum price fx headwind volum gain
russia gulf state partial off-set volum declin south africa saudi
arabia manag note signific invest advertis spend past
year pay improv growth across divis perform across cl eurasia hub
continu improv led russia solid volum price growth aid
combin volum price growth quarter oper profit
higher segment gross profit primarili reflect cost save cl funding-the-
growth initi higher price partial off-set higher raw packag materi cost
incl fx transact cost cl gain toothpast market share turkey morocco kazakhstan
jordan bahrain
final hill organ sale growth robust slightli ahead
estim volum price fx headwind
manag attribut turnaround across hill busi last two year
combin increas market support strong innov growth
primarili led north america manag note everi hub deliv posit price
hub one deliv volum growth manag also upbeat
divis intern perform note result yet reflect impact
compani scienc diet relaunch outsid north america manag note europ grew
volum price behind compani new prescript diet stew busi e-
commerc growth elsewher oper profit decreas lower segment gross
profit primarili reflect higher raw packag materi cost partial off-set cost
save cl funding-the-growth initi higher price
share loss continu cl global toothpast share ytd y/i vs
manual toothbrush share vs last year
 cl toothpast share ytd manual toothbrush
share share loss also continu key countri includ
brazil china india
weak all-in encourag cl organ sale growth across emerg market
acceler vs manag sentiment surround cl emerg
market fundament upbeat echo rel upbeat tone earlier week soft growth
across cl vast emerg market portfolio sourc concern past sever quarter
today result give us confid cl busi like rebound said
nonetheless still hole poke cl emerg market growth lag sever key hpc peer
quarter incl unilev respect report growth
emerg market quarter moreov result sequenti improv china
nonetheless remain neg cl result china challeng step cl taken
reorient compani portfolio oral rapidli premium shift e-
commerc said manag reiter expect signific improv china
move aggress build skin portfolio via acquisit filorga cl
announc acquisit filorga premium skin busi approxim
manag note filorga net sale million period
end june busi also nice profit growth oper margin
cl overal margin first major acquisit new ceo noel wallac
best tell cl largest acquisit year broadli view transact
posit assum multipl paid reasonable/realist given broaden cl
presenc attract skin categori provid entri travel retail channel
particularli asia could provid open extend pca skin eltamd brand
new markets/channel howev biggest take-away us clear sign wallac
aggress re-shap portfolio outsid oral big chang
compani histor run conserv
gross margin inflect posit gross margin y/i ahead
estim first time gross margin y/i year sinc
posit inflect came one quarter ahead expect overal price impact
sale provid lift gross margin save led cl fund
growth product initi provid lift gross margin item
benefit partial off-set higher raw materi cost incl fx transact cost
drag gross margin manag continu expect gross margin
non- basi
guidanc larg maintain manag expect organ sale growth
high-end prior rang net sale growth unchang flat lsd cl
expect benefit price compani product program off-set overal increas
raw materi cost incl fx transact cost elsewher cl expect advertis percent
sale fairli consist level final manag continu expect ep
declin -msd note manag guidanc doesnt includ impact filorga
acquisit expect close
compani report secur llc
cl compani trend pictur
chart compani report secur llc estim
volum price organ sale growth margin net sale rh chang gross margin bp lh y/i chang bp net margin net sale rh chang oper margin bp lh y/i chang bp net incom growth y/i chang y/i chang y/i chang ep y/i chang ex fx y/i chang rh ep growth y/i chang lh ep growth y/i chang ex fx volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net sale cosmet household person
cl compani trend pictur cont
chart compani report secur llc estim
volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net sale colgate-palmol compani
cl compani trend pictur cont
chart compani report secur llc estim
background total relaunch
total relaunch receiv record brand support cl also take price total one cl
largest brand sale manag character relaunch
biggest news brand year histori manag expect relaunch accomplish
host lofti object includ reinvigor brand drive stepped-up custom
engag increas trial/market share cl support launch record amount
market support includ in-stor display promot influenc super bowl ad
accord manag product advertis test gone extrem well retail
commit extraordinari on-shelf support importantli cl simultan take higher price
relaunch via downsiz packag total price per ounc view
part cl broader push innov premium across portfolio
new formul culmin multi-year process total compet multi-benefit
segment toothpast categori given size/success total manag hesit
chang formula unless truli provid better technolog accord cl new
formul culmin develop hold patent anoth
patent pend new colgat total contain benefit old formul antibacteri
plaqu gingiv caviti whiten tartar enamel protect breath also ad host
new benefit includ anti-sensit instant neutral odor increment enamel
protect new flavor importantli new formula also remov triclosan key ingredi
view posit given controversi surround triclosan think cl
made chang year ago
work minim risk relaunch total relaunch shelf mid-februari
 roll global includ brazil reach global market
manag continu view transit soft launch
replac new total old formul sold time hope minim
risk cl take back old inventori said cl take step minim disrupt
still view execut risk heighten given size brand logist complex
cl wide divers global distribut network
size total
colgat total brand share global higher share sever cl key market
includ share brazil share
 track channel colgat total hold share total brand retail sale
repres cl toothpast sale track channel total sale
slow begin late week end
wk notabl significantli higher price reflect result price/mix
volum last total share also weak
last weak result may also due pullback
promot surround relaunch sale promo last
volum price organ sale growth margin net sale rh chang oper margin bp lh y/i chang bp net sale cosmet household person
note grow proport colgat total sale
 non-track channel particularli club mean nielsen result may fulli
repres brand perform
volum price sale growth
sold promo
chart tabl nielsen xaoc includ c-store secur llc
meanwhil toothpast categori improv track channel
categori sale growth though growth acceler back histor
rang categori sale week end
wk categori promot deceler materi sinc last
cl share toothpast track channel cl overal toothpast sale growth
lag categori result share last
chang bp dollar chang bp sold promo colgate-palmol compani
toothpast volum average price/unit growth
toothpast categori sold promo
chart nielsen xaoc includ c-store secur llc
sale y/yeq sale y/yavg eq price y/i sold promo dollar sharedollar share y/i bp retailperiod end end end end end end procter gambl compani smith kline dwight compani channel data chang bp sold promo cosmet household person
histor track record stabil immun macroeconom volatil cl one
world recogniz consum product compani oral care person care home care
pet nutrit product purchas two-third world household
compani global well ahead ko believ cl well-posit
long-term given unmatch distribut platform across emerg market net sale
per-capita outpac develop market long-stand track record
achiev product save cost effici expect compani fund growth cost-
save program remain import contributor gross margin estim individu
contribut gross margin basi point bp annual next sever year
reflect increasingli streamlin global manufactur footprint continu invest
rigor analyt capabl said cl top-lin growth slow materi past
year particularli emerg market believ cl face macroeconomic
competit pressur across global oper previous result see multi-year
period increas invest cl need step invest improv top-lin trajectori
believ dynam like pressur margin could reduc cl long-term ep growth potenti
view cl histor track record oper stabil favor see dynam
competit environ look forward therefor maintain market perform rate
colgate-palmol compani cl financi guidanc secur llcbonni herzog except per-shar data sourc tabl compani report secur llc estimatesguid provid januari call april call juli call fy fy sale end salesflat lsdflat lsdflat advertisinggross margin bp vs ly bp vs ly consist bp vs ly bp vs ly growth growth itemstax provid januari call april call juli call octob call fy sale growth lsd-msd sale msd msd lsddown -lsd advertisinggross margin bp vs ly rel absolutelyup rel absolutelyup rel bp vs ly bp vs ly growth adjust ldd around around itemstax end guidancefi guidanc colgate-palmol compani
price target base follow methodolog forward ev-to-ebitda price-to-earnings
analysi absolut rel discount cash flow analysi
forward ev-to-ebitda absolut rel cl current trade ev/ebitda
multipl premium compani histor averag multipl
premium compani histor averag multipl rel peer
cl current trade roughli in-lin hpc peer group discount rel mega-cap
peer forward ev/ebitda multipl basi compar discount hpc/mega-
cap group histor averag forward ev/ebitda basi discount
hpc/mega-cap group histor averag forward ev/ebitda basi price target impli
ev-to-ebitda multipl discount compani current forward
multipl premium premium histor averag forward ev-
to-ebitda multipl believ appropri consid cl recent top-lin margin challeng
elev competit environ key emerg market
forward price-to-earnings absolut rel cl current trade price-to-earnings multipl
premium compani histor averag multipl premium
compani histor averag multipl rel peer cl current trade in-
line hpc peer group premium rel mega-cap peer forward price-to-earnings multipl
basi compar premium hpc/mega-cap group histor averag
forward price-to-earnings basi premium hpc/mega-cap group histor averag
forward price-to-earnings basi price target impli price-to-earnings multipl discount
compani current forward multipl premium premium
sum-of-the-part discount also valu cl base sum-of-the-part dcf
analysi appropri valu specif opportun cl differ segment base
analysi believ cl worth north america segment worth europ
segment worth latin america segment worth asia pacif segment worth
africa eurasia segment worth pet nutrit segment worth
chart factset secur llc
factset secur llc
chart factset secur llc
compani cl earn varianc sheet secur llcbonni herzog except per-shar data report changenorth profit- inc oper ens relat postretir attribut non-control incom minor share eps- changegross margin normal margin normal compani report secur llc estimatesactu vs estimateactu vs estimateyear/year changesequenti changeyear/year changesequenti chang compani
compani report secur llc estim
colgate-palmol compani cl quarterli earn secur llcbonni herzog except per-shar data sourc tabl compani report secur llc profit- inc oper ens relat postretir attribut non-control incom minor share eps- eps- per america ex ex america ex pacif ex ex ex net net sale ex ex percent salescost good revenu build unless sale stack organ sale colgate-palmol compani
compani report secur llc estim
segment data net organ sale unless note north salesnorth sale ex-currencynorth sale growthnorth sale growth ex-currencynorth net salesnorth data incomenorth segment net segment ebitnorth ebit marginnorth cosmet household person
cl volum average price/unit growth y/i
cl dollar share y/i chang
chart nielsen xaoc includ c-store secur llc
note nielsen quarter-to-d data repres simpl averag nielsen data period follow last period
compani report nielsen xaoc includ c-store secur llc estim
sale y/yeq sale y/yavg eq price y/i sold promo sold promo y/ydollar sharedollar share y/i bp retailperiod end end end end end end end soap-light combin channel data chang bp dollar quarterli north america segment organ sale performanceconsum take-away retail vs manufactur shipment report nielsenreported/estimatedcorrel colgate-palmol compani
exhibit cl european summari data week end
cl european eq volum average price/eq growth y/i
cl european valu share y/i chang
nielsen esp total europ secur llc
nielsen esp total europ secur llc estim
exhibit cl categori result period end
nielsen scantrack total emerg market secur llc
exhibit cl emerg market valu sale volum average price per growth
nielsen scantrack total emerg market secur llc
note growth rate exclud brazil prior
exhibit cl emerg market valu share y/i chang
nielsen scantrack total emerg market secur llc
price target
price target assum price-to-earnings ev-to-ebitda multipl risk price
target includ increment fx headwind local brand competit materi slowdown emerg
cl one attract geograph profil core hpc stapl view said
weak organ sale growth stepped-up invest spend combin high rel valuat
co base new york new york lead consum product compani
produc market oral care home care person care pet nutrit product compani
signific intern presenc market product countri territori world-wide
brand portfolio includ namesak colgat palmol brand also includ number
global brand includ ajax irish spring hill scienc diet softsoap speed stick suavitel
tom main www colgat com
